65 related articles for article (PubMed ID: 24089157)
1. High prevalence of secondary hyperparathyroidism in chronic kidney disease patients on dialysis in Argentina.
Douthat WG; Castellano M; Berenguer L; Guzmán MA; de Arteaga J; Chiurchiu CR; Massari PU; Garay G; Capra R; de La Fuente JL
Nefrologia; 2013; 33(5):657-66. PubMed ID: 24089157
[TBL] [Abstract][Full Text] [Related]
2. Secondary hyperparathyroidism among Nigerians with chronic kidney disease.
Gimba ZM; Abene EE; Agbaji OOO; Agaba EI
Afr Health Sci; 2018 Jun; 18(2):446-457. PubMed ID: 30602972
[TBL] [Abstract][Full Text] [Related]
3. Changes in 3-month mineral and bone disorder patterns were associated with all-cause mortality in prevalent hemodialysis patients with secondary hyperparathyroidism.
Kato C; Fujii N; Miyakoshi C; Asada S; Onishi Y; Fukuma S; Nomura T; Wada M; Fukagawa M; Fukuhara S; Akizawa T
BMC Nephrol; 2020 Oct; 21(1):432. PubMed ID: 33045994
[TBL] [Abstract][Full Text] [Related]
4. Pattern of Laboratory Parameters and Management of Secondary Hyperparathyroidism in Countries of Europe, Asia, the Middle East, and North America.
Cozzolino M; Shilov E; Li Z; Fukagawa M; Al-Ghamdi SMG; Pisoni R; Bieber B; Vallabh B; Chand DH
Adv Ther; 2020 Jun; 37(6):2748-2762. PubMed ID: 32410164
[TBL] [Abstract][Full Text] [Related]
5. The high prevalence of chronic kidney disease-mineral bone disorders: A hospital-based cross-sectional study.
Ghosh B; Brojen T; Banerjee S; Singh N; Singh S; Sharma OP; Prakash J
Indian J Nephrol; 2012 Jul; 22(4):285-91. PubMed ID: 23162273
[TBL] [Abstract][Full Text] [Related]
6. Determinants of hyperparathyroidism in children after kidney transplantation.
Glaberson W; Seeherunvong W; Gaynor JJ; Katsoufis C; Defreitas M; Bao Y; Freundlich M; Ciancio G; Abitbol C; Chandar J
Clin Transplant; 2024 Mar; 38(3):e15284. PubMed ID: 38483311
[TBL] [Abstract][Full Text] [Related]
7. Paricalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients.
Cruzado JM; Lauzurica R; Pascual J; Marcen R; Moreso F; Gutierrez-Dalmau A; Andrés A; Hernández D; Torres A; Beneyto MI; Melilli E; Manonelles A; Arias M; Praga M
Kidney Int Rep; 2018 Jan; 3(1):122-132. PubMed ID: 29340322
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of secondary hyperparathyroidism in patients with stage 3 and 4 chronic kidney disease seen in internal medicine.
Bureo JC; Arévalo JC; Antón J; Adrados G; Jiménez Morales JL; Robles NR;
Endocrinol Nutr; 2015; 62(7):300-5. PubMed ID: 26138703
[TBL] [Abstract][Full Text] [Related]
9. Secondary hyperparathyroidism prevalence and profile, between diabetic and non-diabetic patients with stage 3 to 4 chronic kidney disease attended in internal medicine wards. MiPTH study.
Arévalo-Lorido JC; Carretero-Gómez J; García-Sánchez F; Maciá-Botejara E; Ramiro-Lozano JM; Masero-Carretero A; Robles NR; Bureo-Dacal JC
Diabetes Metab Syndr; 2016; 10(2 Suppl 1):S16-21. PubMed ID: 26916015
[TBL] [Abstract][Full Text] [Related]
10. Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials.
Block GA; Bushinsky DA; Cunningham J; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Mix TC; Moe SM; Patel UD; Silver J; Spiegel DM; Sterling L; Walsh L; Chertow GM
JAMA; 2017 Jan; 317(2):146-155. PubMed ID: 28097355
[TBL] [Abstract][Full Text] [Related]
11. A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM).
Wetmore JB; Gurevich K; Sprague S; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1031-40. PubMed ID: 25904755
[TBL] [Abstract][Full Text] [Related]
12. Impact of parathyroidectomy on cardiovascular outcomes and survival in chronic hemodialysis patients with secondary hyperparathyroidism. A retrospective study of 50 cases prior to the calcimimetics era.
Conzo G; Perna AF; Savica V; Palazzo A; Della Pietra C; Ingrosso D; Satta E; Capasso G; Santini L; Docimo G
BMC Surg; 2013; 13 Suppl 2(Suppl 2):S4. PubMed ID: 24268127
[TBL] [Abstract][Full Text] [Related]
13. Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism.
Komaba H; Taniguchi M; Wada A; Iseki K; Tsubakihara Y; Fukagawa M
Kidney Int; 2015 Aug; 88(2):350-9. PubMed ID: 25786097
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes after parathyroidectomy in a nationwide cohort of patients on hemodialysis.
Ishani A; Liu J; Wetmore JB; Lowe KA; Do T; Bradbury BD; Block GA; Collins AJ
Clin J Am Soc Nephrol; 2015 Jan; 10(1):90-7. PubMed ID: 25516915
[TBL] [Abstract][Full Text] [Related]
15. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients.
Ballinger AE; Palmer SC; Nistor I; Craig JC; Strippoli GF
Cochrane Database Syst Rev; 2014; 2014(12):CD006254. PubMed ID: 25490118
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of paricalcitol versus cinacalcet with low-dose vitamin D for management of secondary hyperparathyroidism in haemodialysis patients in the USA.
Sharma A; Marshall TS; Khan SS; Johns B
Clin Drug Investig; 2014 Feb; 34(2):107-15. PubMed ID: 24214232
[TBL] [Abstract][Full Text] [Related]
17. Secondary Hyperparathyroidism: Pathogenesis and Latest Treatment.
Mizobuchi M; Ogata H; Koiwa F
Ther Apher Dial; 2019 Aug; 23(4):309-318. PubMed ID: 30411503
[TBL] [Abstract][Full Text] [Related]
18. Patellar and quadriceps tendon rupture are associated with hip fracture in hemodialysis patients with severe hyperparathyroidism.
Pichone A; Juvencio EL; Crespo B; Gomes CP; Mendes RS; Godinho MR; Ladeira ACF; Leite M; Guimarães JAM
JBMR Plus; 2024 Feb; 8(2):ziae008. PubMed ID: 38505521
[TBL] [Abstract][Full Text] [Related]
19. High ankle-brachial index predicts cardiovascular events and mortality in hemodialysis patients with severe secondary hyperparathyroidism.
Pichone A; Campos G; Leite M; Gomes CP
J Bras Nefrol; 2021; 43(4):478-485. PubMed ID: 33979425
[TBL] [Abstract][Full Text] [Related]
20. A Bayesian network analysis on comparative efficacy of treatment strategies for dialysis patients with secondary hyperparathyroidism.
Ye H; Ye P; Zhang Z; Hou A; Liang Z; Kong Y
Exp Ther Med; 2019 Jan; 17(1):531-540. PubMed ID: 30651833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
